HealthQuill Coronary Heart Disease
Merck & Co., Inc. has bought global rights for an experimental oral drug to treat heart diseases from China’s Jiangsu Hengrui Pharmaceuticals Co., Ltd. in a $2 billion deal.
Drugs Health Pharma

Merck signs $2b licensing deal with Jiangsu Hengrui for heart disease drug

HQ Team March 25, 2025: Merck & Co., Inc. has bought global rights for an experimental oral drug to treat heart diseases from.

Read More